Final-Program-ATS-2023-AP.vp

MONDAY • MAY 22

179

P1244 SLC7A11 Inhibits Macrophage Efferocytosis and

P1257 Activation of Large Conductance K+ (BK) Channels Protects Against LPS-induced Pneumonia/ T. Zyrianova, Los Angeles, CA P1258 Moderate Hypoxia Does Not Worsen Lung Injury in a Mouse Model of COVID-19/ Y. Xu, La Jolla, CA P1259 Adaptation of Human Lung Endothelial Organotypic Model to Investigate Human Sepsis Patient Plasma/ H.E. Faust, Madison, WI P1260 Role of Apoptosis Signal-regulating Kinase-1 (ASK1) in Influenza A Virus-induced Lung Injury/ E.M. Gordon, Lexington, KY P1261 Neutrophil Heterogeneity Underlies Differential Susceptibility to Pulmonary Vascular Leakage During Murine Hepatitis Virus Strain 1 Infection of A/J and C57BL/6 Mouse Strains/ H.H. Gong, Ann Arbor, MI P1262 Surfactant Protein-D (SP-D) Binding Against the SARS-CoV-2 Spike (S) Protein Using Quantum- and Classical In-silico Modeling: Role of Glycosylation/ A. Haczku, Davis, CA P1263 Effects of Exposure to Environmental Pollution From Iron Ore Pellets on Elastase-induced Lung Inflammation: Evaluation of the Effect of Reduced Acetylcholine Transporter Expression in Mice/ I.C. Tiberio, Sao Paulo, Brazil P1264 Understanding the Impact of Asthma on the Severe Form of COVID-19 Using Genomics/ O. Amri, Saguenay, Canada P1265 Inhibition of Sphingolipid Synthesis Decreases SARS-CoV-2 Infection in Human Airway Epithelial Cells/ R. Gomi, New York, NY P1266 Neutrophil Reduction Attenuates the Severity of Acute Lung Injury in the Early Phase of Pneumococcal Pneumonia in Mice/ H. Taenaka, San Francisco, CA P1267 Lung Interstitial Macrophage Dynamics and Phenotypes After Pneumococcal Respiratory Infection/ E.M.R. Armstrong, Boston, MA P1268 The Role of the IL-1ß Pathway in Severe Acute Respiratory Syndrome Coronavirus 2 Infection of Human Airway Epithelia/ A. Singh, Chapel Hill, NC P1269 Age-specific Responses of Yes-associated Protein to Pneumonia-induced Acute Lung Injury/ R.F. Hough, New York, NY P1270 Long Noncoding RNA Lncenc1 Deficiency Protects Mice From Bacteria-induced Acute Lung Injury/ Y. Zhu, Augusta, GA P1271 Role of A4-containing Nicotinic Acetylcholine Receptors (a4 nAChRs) in Lipopolysaccharide-induced Lung Injury/ J. Roman, Philadelphia, PA

Promotes Pro-fibrotic Macrophage Phenotype in Fibrotic Remodeling of the Lung/ M. Patil, Birmingham, AL

P1245 Reprogramming Rogue Macrophages: Yeast Beta-glucan Microparticles as a Macrophage Modulator for Lung Fibrosis/ S. Naiel, Hamilton, Canada P1246 Mechanosignaling Modulates Macrophage Profibrotic Polarization Epigenetically/ C. He, Birmingham, AL P1247 Peripheral Immune Cell Profiling Reveals Distinct Immune Hallmarks in Progressive Pulmonary Fibrosis/ F. Hernandez-Gonzalez, Barcelona, Spain P1248 Unbiased Identification of Serum Response Factor as a Central Profibrotic Mechanism in Idiopathic Pulmonary Fibrosis/ H. Olsson, Gothenburg, Sweden P1249 Mast Cell-expressed Membrane Protein 1 (MCEMP1) Deficient Mice May Be Protected Against Bleomycin-induced Pulmonary Fibrosis In Vivo/ C.Y. Perrot, Tampa, FL P1250 Expression of PD-1/PD-L1 Axis and CD4/CD8 Ratio in Mediastinal Lymph Nodes of Human and Experimental Lung Fibrosis Indicates a Potential Therapeutic Target for Idiopathic Pulmonary Fibrosis/ T. Karampitsakos, Patras, Greece P1251 Growth and Differentiation Factor-15 (GDF15) Is Associated With Vascular Remodeling in Pulmonary Fibrotic Disease/ K. Raffensperger, Pittsburgh, PA P1252 The mTOR Strikes Back: Vaping Liquid Induced mTOR Hyperactivation in Lymphangioleiomyomatosis (LAM) Exacerbates Endothelial Cell Apoptosis and Impairment of Network Formation Via Senescence Associated Secretory Phenotype (SASP) Factors/ M. Ho, Toronto, Canada P1253 Circulating Extracellular Vesicles Isolated From Young Mice Protect Endothelial Cells and Exert Anti-fibrotic Effects In Vivo and Ex Vivo/ F. Gianì, Rochester, MN P1254 Myeloid-Dependent Immunosuppressive Features Drive IPF Progression/ I.E. Fernandez, Munich, Germany

BASIC • TRANSLATIONAL THEMATIC POSTER SESSION

B66

BUG’S LIFE: FROM PNEUMONIA TO SEPSIS

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area L, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussionwith assigned facilitators.

ATS 2023 • Washington, DC